Madrigal Pharmaceuticals, Inc. (LON:0JXI)
530.89
+12.23 (2.36%)
At close: Nov 14, 2025
Madrigal Pharmaceuticals Revenue
Madrigal Pharmaceuticals had revenue of $287.27M USD in the quarter ending September 30, 2025, with 362.03% growth. This brings the company's revenue in the last twelve months to $740.64M, up 864.21% year-over-year. In the year 2024, Madrigal Pharmaceuticals had annual revenue of $180.13M.
Revenue (ttm)
$740.64M
Revenue Growth
+864.21%
P/S Ratio
16.58
Revenue / Employee
$1.40M
Employees
528
Market Cap
9.13B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 180.13M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 200.18B |
| BP p.l.c. | 138.32B |
| Unilever | 51.24B |
| AstraZeneca | 43.24B |
| HSBC Holdings | 43.13B |
| Rio Tinto Group | 39.22B |
| GSK plc | 32.17B |
| Barclays | 26.02B |